Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: The SAMURAI-NVAF Study

International Journal of Stroke

Volumn 10, Issue 6, 2015, Pages 836-842

  Toyoda, Kazunori ^a   Arihiro, Shoji ^a   Todo, Kenichi ^b   Yamagami, Hiroshi ^a   Kimura, Kazumi ^c   Furui, Eisuke ^d   Terasaki, Tadashi ^e   Shiokawa, Yoshiaki ^f   Kamiyama, Kenji ^g   Takizawa, Shunya ^h   Okuda, Satoshi ⁱ   Okada, Yasushi ^j   Kameda, Tomoaki ^k   Nagakane, Yoshinari ^l   Hasegawa, Yasuhiro ^m   Mochizuki, Hiroshi ⁿ   Ito, Yasuhiro ^o   Nakashima, Takahiro ^p   Takamatsu, Kazuhiro ^q   Nishiyama, Kazutoshi ^r   Kario, Kazuomi ^k   Sato, Shoichiro ^a   Koga, Masatoshi ^a   more..

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d KOHNAN HOSPITAL   (Japan)

^e JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

^f KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g Nakamura Memorial Hospital   (Japan)

^h TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^k JICHI MEDICAL UNIVERSITY   (Japan)

^l KYOTO SECOND RED CROSS HOSPITAL   (Japan)

^m ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ South Miyagi Medical Center   (Japan)

^o TOYOTA MEMORIAL HOSPITAL   (Japan)

^p NATIONAL HOSPITAL ORGANIZATION KAGOSHIMA MEDICAL CENTER   (Japan)

^q Subaru Health Insurance Society Ota Memorial Hospital   (Japan)

^r KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Acute stroke care; Anticoagulation; Atrial fibrillation; Embolism; Prevention

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; NONVITAMIN K ANTAGONIST ORAL ANTICOAGULANT; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN;

AGE DISTRIBUTION; AGED; ARTICLE; ATRIAL FIBRILLATION; BODY WEIGHT; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; CHADS2 SCORE; CLINICAL STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ELECTROCARDIOGRAPHY; FEMALE; HAS BLED SCORE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NONVALVULAR ATRIAL FIBRILLATION; ONSET AGE; PRIORITY JOURNAL; PROTHROMBIN TIME; RANKIN SCALE; RATING SCALE; SCORING SYSTEM; SEX DIFFERENCE; STROKE PATIENT; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREND STUDY; VERY ELDERLY; BRAIN ISCHEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; COMPLICATION; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; REGISTER; SEVERITY OF ILLNESS INDEX; STROKE; TRENDS;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; FEMALE; HOSPITALIZATION; HUMANS; JAPAN; MALE; MULTIVARIATE ANALYSIS; PRACTICE PATTERNS, PHYSICIANS'; REGISTRIES; SEVERITY OF ILLNESS INDEX; STROKE;

EID: 84938213598     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12452     Document Type: Article

References (22)

1. Husted S, de Caterina R, Andreotti F etal. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. Thromb Haemost 2014; 111:781-782.
2. Connoly SJ, Ezekowitz MD, Yusuf S etal. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
3. Patel MR, Mahaffey KW, Garg J etal. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
4. Granger CB, Alexander JH, McMurray JJ etal. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-992.
5. Giugliano RP, Ruff CT, Braunwald E etal. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093-2104.
6. Diener HC, Connolly SJ, Ezekowitz MD etal. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack orstroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9:1157-1163.
7. Hankey GJ, Patel MR, Stevens SR etal. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11:315-322.
8. Easton JD, Lopes RD, Bahit MC etal. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11:503-511.
9. Hori M, Connolly SJ, Zhu J etal. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013; 44:1891-1896.
10. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost 2014; 111:789-797.
11. Gage BF, Waterman AD, Shannon W etal. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864-2870.
12. Lip GY, Nieuwlaat R, Pisters R etal. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137:263-272.
13. Pisters R, Lane DA, Nieuwlaat R etal. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138:1093-1100.
14. Camm AJ, Lip GY, De Caterina R etal. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33:2719-2747.
15. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circ J 2014; 78:1997-2021.
16. January CT, Wann LS, Alpert JS etal. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014; 130:2071-2104.
17. Ruff CT, Giugliano RP, Braunwald E etal. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383:955-962.
18. Okata T, Toyoda K, Okamoto A, Miyata T, Nagatsuka K, Minematsu K. Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in Japan. PLoS One 2014; 9:e113641.
19. Toyoda K, Ninomiya T. Stroke and cerebrovascular diseases in patients with chronic kidney disease. Lancet Neurol 2014; 13:823-833.
20. Kernan WN, Ovbiagele B, Black HR etal. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45:2160-2236.
21. Heidbuchel H, Verhamme P, Alings M etal. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15:625-651.
22. Shibazaki K, Kimura K, Aoki J etal. Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. J Neurol Sci 2013; 331:90-93.